Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1408-1414, 2007. First published June 22, 2007; 10.1373/clinchem.2007.086595
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow 086595.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.086595v1
53/8/1408    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laurent, P.
Right arrow Articles by Michault, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurent, P.
Right arrow Articles by Michault, A.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2007;53:1408-1414.)
© 2007 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Development of a Sensitive Real-Time Reverse Transcriptase PCR Assay with an Internal Control to Detect and Quantify Chikungunya Virus

Philippe Laurent1, Karin Le Roux1, Philippe Grivard1, Gérard Bertil1, Florence Naze1, Miguel Picard1, Frédérik Staikowsky2, Georges Barau3, Isabelle Schuffenecker4 and Alain Michault1,a

Services de1 Bactériologie-Parasitologie-Virologie et Hygiène,2 Urgences, and3 Gynécologie-Obstétrique, Groupe Hospitalier Sud Réunion, Saint-Pierre, La Réunion.
4 Institut Pasteur, Centre National de Référence pour les Arbovirus, Lyon, France.

aAddress correspondence to this author at: Service de Bactériologie-Parasitologie-Virologie et Hygiène, Groupe Hospitalier Sud Réunion, BP 350, Saint-Pierre Cédex 97448, La Réunion. Fax 00-262-262-35-97-13; e-mail a.michault{at}ch-sudreunion.fr.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Background: The chikungunya virus (CHIKV; Alphavirus, Togaviridae) has emerged in the south Western Indian Ocean since early 2005. A major outbreak of CHIKV infection occurred in Réunion Island, where the virus is transmitted by Aedes albopictus mosquitoes. Facing an outbreak of unprecedented magnitude, we developed a rapid, sensitive, and reliable assay for the detection and quantification of CHIKV in plasma samples.

Methods: A dual-color TaqMan 1-step reverse transcriptase PCR assay was developed in a LightCycler 2.0 system. A coextracted and coamplified chimerical RNA sequence was used as an internal control (IC) to eliminate false-negative results. The CHIKV-specific and IC probes were labeled with 6-carboxyfluorescein (530 nm) and the wide span dye DYXL (705 nm), respectively, eliminating the need for color compensation. A synthetic RNA was used as an external calibrator for CHIKV absolute quantification.

Results: The detection limit was 350 copies/mL (3 copies/capillary). A further improvement to ~40 copies/mL was obtained by use of a larger volume of plasma. The assay specificity was confirmed in vitro and in silico. CHIKV in 343 patients was present at viral loads >108 copies/mL, mainly in newborns and seniors >60 years old. Long viremic phases of up to 12 days were seen in 6 patients.

Conclusions: The assay is rapid, CHIKV-specific, and highly sensitive, and it includes an IC. It proved useful to detect and quantify CHIKV during the Réunion Island epidemic. The assay might be applicable to other CHIKV epidemics, especially in the Indian subcontinent, where an extensive outbreak is ongoing.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Chikungunya virus (CHIKV)1 is an arthropod-borne virus (arbovirus) transmitted to humans by mosquitoes belonging to the Aedes genus. CHIKV is an enveloped, single-strand positive RNA Alphavirus in the Togaviridae family (1). CHIKV infection produces a human disease characterized by fever, arthralgia, and maculopapular rash (2). Other symptoms, such as headache, asthenia, nausea, vomiting, myalgia, and dysgeusia, have also been described (2)(3). Severe clinical signs such as hepatitis or encephalopathy were also reported during the Réunion 2005–2006 outbreak (2)(3). Symptoms usually appear after 2–4 days of incubation and may disappear after a few days, but arthralgia may persist for months or even years (4).

Since the virus was isolated in Tanzania in 1952 (5), many CHIKV outbreaks have occurred in Eastern, Southern, Central, and Western Africa (6)(7). CHIKV was also reported in Asia (8)(9)(10) and India (11). Phylogenetic analyses based on partial glycoprotein E1 nucleotide sequences revealed the existence of 3 distinct phylogroups: West African, East-Central-South African (ECSA), and Asian (3)(7). It was also shown that CHIKV initially originated in Africa and was introduced in Asia (7). Recent extensive outbreaks of chikungunya fever in the Indian subcontinent confirmed the reemergence of the virus in 2006 in 3 states of India (12). Since the beginning of 2005, CHIKV has emerged in several Indian Ocean islands (Comoros, Réunion, Mauritius, Seychelles, and Madagascar) (13)(14). The vector involved in Réunion Island was the Asian tiger mosquito Aedes albopictus (15). The analysis of 6 complete genome sequences and 127 E1 sequences showed that the Indian Ocean isolates share a common origin and belong to a distinct cluster within the ECSA phylogroup (3). Moreover, a specific mutation in the E1 sequence (A226V) was selected during the Indian Ocean outbreaks. The mutation was absent in the initial strains (March to June 2005) and was subsequently observed in >90% of strains after September 2005. The mutation is believed to confer to the virus a selective advantage in A. albopictus (3).

Diagnosis of CHIKV infection is mostly based on serological and PCR techniques (1). Virus cultures followed by detection of viral antigens is a sensitive method but must be performed under BSL3 biosafety conditions and is time consuming. This method is therefore used only for virus identification at the beginning of an epidemic. Serological methods are reliable but are not appropriate in early stage infection, i.e., before 5–6 days after the clinical onset. Nucleic acid amplification by PCR is an appropriate diagnostic tool at an early stage of infection, while the patient is viremic (16). Real-time reverse transcriptase PCR (RT-PCR), in particular, has been developed for the detection of several arboviruses (17)(18)(19)(20), including CHIKV (21). Real-time RT-PCR allows the initial genome concentration to be quantified and therefore the viral load to be accurately determined. However, RT-PCR detection assays should include the extraction and the amplification of an internal control (IC) because numerous PCR inhibitors may be present in human samples (16)(22).

We developed a rapid, sensitive, and reliable RT-PCR assay that involves the coextraction and amplification of an IC. We used the assay as a diagnostic tool for the detection and quantification of CHIKV genomes in plasma samples. We determined the analytical sensitivity and specificity of the assay and the viral load for patients of different ages with typical chikungunya symptoms.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
patients and samples
All the CHIKV-positive patients reported in this study (n = 343) were admitted to the hospital between October 2005 and June 2006 with chikungunya acute symptoms. A total of 169 blood samples were obtained from the emergency care unit and 174 from other units of the hospital. Patients from the emergency unit had detailed clinical files.

CHIKV-negative samples (n = 112) were tested to evaluate the specificity of the assay. Among them, 10 were positive for, respectively, human enterovirus, HIV, hepatitis C virus, hepatitis B virus, cytomegalovirus, Epstein–Barr virus, herpes simplex virus, varicella-zoster virus, dengue virus, and West Nile virus. The 102 remaining samples were obtained during the 2005 southern hemisphere winter, when CHIKV transmission was low, from patients admitted to the hospital for other diseases than chikungunya fever.

Whole blood was collected in 5 mL EDTA-Vacutainer Tubes (Becton Dickinson Vacutainer System) and centrifuged 15 min at 2000g. The clarified plasma samples were stored at –80 °C as 250-µL aliquots.

extraction of viral rna
Viral RNA was extracted from 200 µL of thawed samples using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics) according to the manufacturer’s instructions. To improve sensitivity, large-volume extractions were also performed from 500 µL of thawed samples using the Large Volume MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics). In both cases, nucleic acids were recovered in 50 µL of elution buffer and immediately subjected to molecular analysis. For routine analysis and large-volume analysis, the lysis buffer was enriched with IC RNA (see below) at a concentration of 1.83 x 105 copies/mL and 3.65 x 104 copies/mL, respectively. The final concentration in both cases was 282 copies/capillary. The lysis buffer enriched with IC RNA was cooled to 4 °C before extraction.

single-step sybr green rt-pcr
We performed RT-PCR amplifications with the LightCycler® 2.0 system (Roche Diagnostics). Four primers located in the glycoprotein E1 gene were selected among published sequences (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol53/issue8). Assay conditions were optimized using the LightCycler RNA Master SYBR Green I Kit (Roche Diagnostics). The 20-µL reaction mix contained 2 µL of positive control RNA, 7.5 µL of LightCycler RNA Master SYBR Green I, 3.25 mmol/L Mn2+, and each forward and reverse primer at a concentration of either 150, 300, or 450 nmol/L. The thermal cycling consisted of a reverse transcription at 61 °C for 20 min, followed by 40 cycles at 95 °C for 5 s, 57 °C for 10 s, and 72 °C for 15 s. The fluorescence was measured at 530 nm. After amplification, a melting curve analysis was performed to identify the amplicons by their specific melting temperatures (Tm). The melting curve analysis consisted of a denaturation step at 95 °C for 5 s, a temperature decrease to 55 °C for 15 s, and a temperature increase to 95 °C (0.1 °C/s) with continuous measurement of the fluorescence.


View this table:
[in this window]
[in a new window]

  		Table 1. Detection rate and intraexperimental reproducibility of the CHIKV TaqMan RT-PCR assay.

TAQMAN® real-time rt-pcr
Amplifications were performed using the LightCycler 2.0 system (Roche Diagnostics). Assay conditions were optimized using various primer concentrations and the LightCycler RNA Master Hybridization Probe Kit (Roche Diagnostics). The 20 µL reaction mix contained 2 µL of extracted RNA, 7.5 µL of LightCycler RNA Master HybProbe, 3.25 mmol/L Mn2+, 450 nmol/L ChikF1 primer, 150 nmol/L ChikR1 primer, 150 nmol/L ChikProb (5' 6-carboxyfluorescein-3' TAMRA), and 50 nmol/L ICProb (5' DYXL-3' BHQ2) fluorescent-labeled probes (TibMolBiol). The thermal cycling consisted of a reverse transcription at 61 °C for 20 min followed by 45 cycles at 95 °C for 5 s and 60 °C for 15 s. The fluorescence was measured at 530 nm.

Large-volume assays were performed with the TaqMan RNA Amplification Kit (Roche Diagnostics). The 100 µL reaction mix contained 10 µL of extracted RNA, 20 µL of TaqMan RNA Reaction Mix, 2 mmol/L Mn2+, 450 nmol/L ChikF1 primer, 150 nmol/L ChikR1 primer, 150 nmol/L ChikProb, and 50 nmol/L ICProb. RT-PCR cycling was carried out as follows: precycle #1, 50 °C for 5 min (AmpErase); precycle #2, 95 °C for 1 min; and precycle #3, 60 °C for 30 min (reverse transcription). Precycles were followed by 40 cycles at 95 °C for 10 s and 60 °C for 30 s. The fluorescence was measured at 530 nm.

The data were analyzed with LightCycler Software Version 4.05. The CT (cycle threshold) for each sample was calculated using the 2nd derivative maximum algorithm. Each test run included a water negative control and a positive control.

external calibrator
A synthetic RNA was used as an external calibrator for CHIKV absolute quantification. The target sequence was amplified by RT-PCR, purified using the GeneClean Turbo Kit (Qbiogene), and cloned into the T7 expression vector pGEM-T Easy® (Promega). For in vitro transcription, a 524-bp DNA fragment, encompassing the complete CHIKV target sequence and the T7 promoter, was amplified with vector-specific primers. The resulting fragments were purified using the GeneClean Turbo Kit (Qbiogene) and in vitro transcribed using the Riboprobe® T7 System (Promega). The 439-bp RNA transcripts were purified using the RNeasy® MinElute® Kit (Qiagen) and the amount of RNA was estimated using the Quant-iT® RiboGreen® RNA Kit (Molecular Probes) as described by the manufacturers.

ic
A chimerical RNA was used as an IC. It consisted of a 45-bp enterovirus target sequence (Coxsackievirus A16, position 537 to 581, GenBank accession no. U05876), lengthened by a 5-step PCR using 5 pairs of partially overlapping oligonucleotides. The resulting 209-bp DNA fragment was flanked by ChikF and ChikR primer target sequences and displayed the same GC content as the corresponding CHIKV DNA fragment. The IC DNA was cloned, in vitro transcribed, and treated with DNase to remove all residual DNA contamination. The RNA amount was estimated as described above, and the transcript was stored at –80 °C in PCR-grade water.

The IC RNA sequence was RT-PCR amplified using the ChikF1 and ChikR1 primers and detected by the IC specific fluorescent-labeled probe ICProb (5' DYXL-3' BHQ2; TibMolBiol). DYXL is excited at 470 nm and detected at 705 nm. BHQ2 is a nonfluorescent "black hole" quencher.

sequence alignments
Multiple sequence alignments of E1 gene sequences were performed using ClustalX 1.8 (23) to evaluate the specificity of the CHIKV primers and probe (see Table 1Up in the online Data Supplement). A total of 47 sequences were retrieved from the GenBank database, and 127 partial E1 nucleotides sequences were available from a previous study (3).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
design and screening of primer pairs using a single-step sybr green rt-pcr
Primers used in our study are located in glycoprotein E1-conserved regions as described previously (21). Four specific primers were designed: 2 forward primers (ChikF1, ChikF2) and 2 reverse primers (ChikR1, ChikR2; see Table 1Up in the online Data Supplement). The 4 primer combinations were tested using a single-step SYBR Green RT-PCR. The concentration for each primer and the thermal cycling were optimized to increase sensitivity. The specificity was verified by melting curve analysis of the amplicons. The Tm values for primer dimers were <75 °C, and the Tm for the CHIKV-specific fragment was 82 °C. The optimal primer concentrations were 450 nmol/L for the forward primer and 150 nmol/L for the reverse primer. The best sensitivity (smallest CT value) was achieved with the ChikF1/ChikR1 pair. This result was in accordance with the E1 sequences, which were determined from 127 patients during the Indian Ocean outbreak (3). No mismatch was observed between the ChikF1/ChikR1 primers and the Indian Ocean CHIKV sequences. The CT value was 1 cycle higher when we used any of the 3 other primer combinations instead of ChikF1/ChikR1.

To develop a TaqMan RT-PCR assay, the specificity of the TaqMan probe (ChikProb) was also checked using sequence alignments. No mismatch was observed with the Indian Ocean CHIKV sequences. However, 1 Indian strain (GenBank accession no. DQ888620) and 4 West African strains (AF192891, AF192892, AF192893, and AY726732) showed 1 and 2 mismatches, respectively (see Table 1Up in the online Data Supplement).

sensitivity and reproducibility of the TAQMAN rt-pcr assay
Ten-fold serial dilutions of the RNA external calibrator were done in CHIKV-negative plasma, resulting in concentrations ranging from 102 to 109 copies/mL. Dilutions of RNA were extracted and amplified in triplicates in the same run, to evaluate the intraexperimental reproducibility. The mean CT values were plotted against the copy number to establish a calibration curve (see Fig. 1 in the online Data Supplement). The correlation coefficient was >0.998 and the slope was –3.38. The amplification efficiency, calculated as 10(–1/slope), was 1.97. The assay was reproducible; SDs of CT values were <0.31 (Table 1Up ). The detection limit was between 102 and 103 copies/mL. The linear detection range was 103 to 109 copies/mL. To refine the estimate of the detection limit, additional dilutions of the RNA calibrator were extracted and amplified in triplicate. The last dilution to be amplified with a detection rate of 100% corresponded to a mean (SD) of 353 (17) copies/mL, according to the calibration curve (see Fig. 1 in the online Data Supplement), corresponding to 2.9 (0.14) copies/capillary. This finding is consistent with the Poisson distribution, which predicts that 95% of replicates will be positive for a mean concentration of 2.9 copies per reaction mix (24). When using the large-volume protocol, the detection threshold was decreased to 42 (4.2) copies/mL, which corresponded to 4.21 (0.4) copies/capillary. The interassay variability was evaluated by amplifying a sample containing 103 copies/mL in 15 different runs. The mean CT value was 29.01, with a low SD of 0.26 cycles (data not shown).


Figure 1
View larger version (40K):
[in this window]
[in a new window]

  		Figure 1. Proportional distribution of age classes against CHIKV load for 343 studied patients.

White circles represent babies less than 1 year of age. The age class percentages (%) are given inside proportional circles. The population sizes (n) are indicated.

implementation of the ic
A chimerical RNA was used as IC to eliminate false-negative results due to PCR inhibition and extraction failure. The RT-PCR protocol consisted of a dual-color assay with heterologous probes to detect the CHIKV target and the IC sequences, which were both amplified by ChikF1/ChikR1. Several IC concentrations were tested to decrease competition with CHIKV RNA amplification. The optimal IC concentrations that allowed the same sensitivity for CHIKV target amplification were 1.83 x 105 copies/mL and 3.65 x 104 copies/mL for the routine and large-volume protocols, respectively. This corresponded, after extraction, to a final concentration of 282 copies/capillary in both cases. The optimal concentrations were obtained using the lowest IC probe concentration that allowed reliable detection (50 nmol/L). CHIKV target and IC sequences were specifically detected at 530 nm and 705 nm, respectively, with no fluorescence cross-talk. Nevertheless, inhibition of the IC amplification occurred in the presence of high CHIKV RNA target concentrations. This was not detrimental, however, because IC is used to monitor false-negative results.

chikv TAQMAN rt-pcr specificity
In addition to the in silico specificity described above, a panel of arboviruses and other viruses commonly found in blood was used to verify the in vitro specificity of the CHIKV TaqMan RT-PCR after 45 amplification cycles. No amplification was obtained from samples that were positive for human enterovirus, HIV, hepatitis C virus, hepatitis B virus, cytomegalovirus, Epstein–Barr virus, herpes simplex virus, varicella-zoster virus, dengue virus, and West Nile virus. Moreover, 102 CHIKV-negative samples obtained from patients admitted to the hospital for diseases other than chikungunya fever tested negative using the CHIKV TaqMan RT-PCR assay. In each case, the IC was successfully extracted, amplified, and detected.

chikv quantification from infected patients
We used the CHIKV TaqMan RT-PCR assay to test 343 patients with acute symptoms of chikungunya fever; all were positive. The proportional distribution of age classes was plotted against viral load (Fig. 1Up ). The proportion of patients <20 years of age increased with viral load, especially for newborns (white circles). Inversely, the proportion of patients between 20 and 60 years of age decreased with viral load. Patients with viral loads >108 copies/mL were mainly newborns and adults >60 years olds (40.80% and 40.81%, respectively).

The 343 patients included 169 emergency care unit patients, from whom samples were collected between the 1st and 12th day after the onset of the symptoms. Viral load ranged from 2.91 x 104 to 8.55 x 108 copies/mL. For 89% of these patients blood was collected within the first 3 days after the symptoms appeared (Fig. 2 ). These emergency care unit patients were mainly adults (98.7% >16 years old), and mean age increased with viral load in a nonlinear fashion (Fig. 3 ).


Figure 2
View larger version (27K):
[in this window]
[in a new window]

  		Figure 2. CHIKV load in plasma from 169 emergency unit patients.

The viral loads (diamonds) are plotted against the time after first development of symptoms. The proportions of total patients are represented for each day as gray stacks.


Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		Figure 3. Mean age of 169 emergency unit care patients against CHIKV load.

SD values are represented as error bars.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Since early 2005, Réunion Island has been suffering from a large-scale outbreak of chikungunya fever. CHIKV has infected one-third of the population, i.e., ~300 000 people. Several patients developed severe clinical signs such as meningoencephalopathy (3), and 249 death certificates mentioned "chikungunya" as a comorbidity factor (25). Mother-to-child transmission of the virus was reported (26). This outbreak of unprecedented magnitude necessitated the development of a rapid, sensitive, and reliable CHIKV-detection assay.

Our dual-color TaqMan RT-PCR technique was CHIKV specific, as verified both in silico and on 112 clinical samples. We achieved better sensitivity and wider linear range than previously reported (21)(27). In addition, the use of a coextracted and coamplified IC allowed the detection of false-negative results due to PCR and/or extraction failures. To eliminate the need for color compensation in the LightCycler 2.0 platform, we chose DYXL as an IC fluorescent reporter. Its emission spectrum (705 nm) does not overlap with the 6-carboxyfluorescein emission spectrum (530 nm). Compared with conventional RT-PCR techniques, our assay was rapid and could be performed in 2 h, including the MagNA Pure nucleic acid extraction. Furthermore, the use of single closed capillaries eliminated the risk of contamination.

No RT-PCR inhibition was observed for the 343 plasma samples tested during this study. However, inhibition occurred for 2% of CHIKV-positive and -negative plasma samples tested in routine analysis since the beginning of the outbreak. This result emphasizes the importance of using an IC to provide a reliable clinical diagnosis. For instance, the use of a coextracted IC enabled the detection method to be adapted to a maternal milk specimen, as 100% were inhibitory using the plasma extraction technique (data not shown).

Our routine assay allowed the detection of 353 (17) copies/mL in plasma samples [2.9 (0.14) copies/capillary] and was therefore sensitive enough to diagnose all clinical cases, because we found no viral load <104 copies/mL in all 343 plasma samples. The large-volume protocol reached an even greater sensitivity of 42 (4.2) copies/mL. This increased sensitivity was useful for types of samples other than plasma, such as cerebrospinal fluids, in which viral loads were, on average, 25 000 times lower than in blood (28). The large-volume protocol was also useful for blood donor screening. Blood donation had stopped in Réunion Island, because no reliable test was available before we developed our assay. The high sensitivity was important for detection of viremic donors without clinical signs (incubation period or asymptomatic cases). These individuals might have low viral loads, as previously shown in asymptomatic patients infected with the West Nile virus (29)(30).

In our study, 6 patients showed a longer CHIKV viremic phase than previously reported (5–6 days) (31). CHIKV RNA was detected up to 12 days after the clinical onset, with high viral load (6 105 to 1.3 x 107 copies/mL). Longer viremia might be due to a delayed or less efficient immune response, because CHIKV-specific IgM were not detected in these patients (data not shown). No correlation with age was observed; patients were of various ages: 32, 46, 52, 62, 84, and 86 years old. The high viral load at 12 days suggested that the virus might circulate for an even longer period.

In our study, patients with high viral loads (>108 copies/mL) were mainly newborns (40.8%) and older adults >60 years old (40.81%). These 2 populations may have a less efficient immune response, allowing a higher rate of virus replication.

Sequence alignments showed that our RT-PCR assay is applicable to the entire Indian Ocean region and the Indian Subcontinent. Isolates from the Southern Indian Ocean outbreak and the current outbreak in India are closely related and belong to the African genotype (3)(11)(12)(32).

Our TaqMan RT-PCR assay can also be useful to detect CHIKV among travelers coming from epidemic regions where the ECSA genotype circulates. Transmission in Réunion Island began with travelers coming from the Comoros islands. During 2006, numerous imported cases of chikungunya fever were diagnosed among travelers returning from Réunion, Seychelles, Mauritius, Madagascar, and India (31)(33). A total of 766 imported cases of chikungunya have been identified in mainland France (i.e., excluding overseas departments and territories) since the beginning of the Indian Ocean outbreak (34). Because A. albopictus has already been introduced into several European countries (35)(36)(37), autochthonous CHIKV transmission is theoretically possible but has not been reported to date (33). The risk for autochthonous CHIKV transmission by mosquitoes has been taken into consideration in mainland France, and reinforced surveillance has been organized in the areas where the mosquito is present.

In conclusion, our laboratory developed a highly sensitive and reliable dual-color TaqMan 1-step RT-PCR assay for the detection and the quantification of CHIKV in plasma samples. In several tropical regions, arbovirus diseases are emerging or reemerging in a cyclical way (11)(15)(32)(38). The ongoing chikungunya epidemic in the Indian Ocean, as well as the 1978 (39) and 2004 Dengue virus-1 (40) outbreaks in Réunion Island provided evidence that other arbovirus outbreaks are likely to occur. Based on such perspective we are currently developing a multiplex real-time RT-PCR assay for the detection of a range of arboviruses.


   Acknowledgments
 
Grant/funding support: None declared.

Financial disclosures: None declared.

Acknowledgments: We thank Sheila Bonari for proofreading the manuscript.


   Footnotes
 
1 Nonstandard abbreviations: CHIKV, Chikungunya virus; ECSA, East-Central-South African; RT-PCR, reverse transcriptase PCR; IC, internal control; Tm, melting temperature; CT, cycle threshold.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Johnston RE, Peters CJ. Alphaviruses associated primarily with fever and polyarthritis. Fields BN Knipe DM Howley PM eds. Fields Virology 1996:843-898 Lippincott-Raven Publishers Philadelphia. .
  2. Staikowsky F, Pinar A, Cand E, Grivard P, Tallermin F, Michault A. The infection by the virus chikungunya: an emergent disease in the Reunion island. Eur J Emerg Med 2006;13:7-8.
  3. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 2006;3:e263.[CrossRef][Medline] [Order article via Infotrieve]
  4. Brighton SW, Prozesky OW, de la Harpe AL. Chikungunya virus infection: a retrospective study of 107 cases. S Afr Med J 1983;63:313-315.[Web of Science][Medline] [Order article via Infotrieve]
  5. Ross RW. The Newala epidemic: III: the virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 1956;54:177-191.[Medline] [Order article via Infotrieve]
  6. Diallo M, Thonnon J, Traore-Lamizana M, Fontenille D. Vectors of chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg 1999;60:281-286.[Abstract]
  7. Powers AM, Brault AC, Tesh RB, Weaver SC. Re-emergence of chikungunya and O’nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. J Gen Virol 2000;81:471-479.[Abstract/Free Full Text]
  8. Thaikruea L, Charearnsook O, Reanphumkarnkit S, Dissomboon P, Phonjan R, Ratchbud S, et al. Chikungunya in Thailand: a re-emerging disease?. Southeast Asian J Trop Med Public Health 1997;28:359-364.[Medline] [Order article via Infotrieve]
  9. Lam SK, Chua KB, Hooi PS, Rahimah MA, Kumari S, Tharmaratnam M, et al. Chikungunya infection: an emerging disease in Malaysia. Southeast Asian J Trop Med Public Health 2001;32:447-451.[Medline] [Order article via Infotrieve]
  10. Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, Djauzi, et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 2005;99:128-141.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  11. Ravi V. Re-emergence of chikungunya virus in India. Ind J Med Microbiol 2006;24:83-84.
  12. Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep AB, Gandhe SS, et al. Chikungunya outbreaks caused by African genotype, India. Emerg Infect Dis 2006;12:1580-1583.[Web of Science][Medline] [Order article via Infotrieve]
  13. Bonn D. How did chikungunya reach the Indian Ocean?. Lancet Infect Dis 2006;6:543.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  14. Depoortere E, Coulombier D. Chikungunya risk assessment for Europe: recommendations for action. Euro Surveill 2006;11:E060511.2.
  15. Reiter P, Fontenille D, Paupy C. Aedes albopictus as an epidemic vector of chikungunya virus: another emerging problem?. Lancet Infect Dis 2006;6:463-464.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  16. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci 2005;109:365-379.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  17. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002;40:2323-2330.[Abstract/Free Full Text]
  18. Shu PY, Chang SF, Kuo YC, Yueh YY, Chien LJ, Sue CL, et al. Development of group- and serotype-specific one-step SYBR Green I-based real-time reverse transcription-PCR assay for dengue virus. J Clin Microbiol 2003;41:2408-2416.[Abstract/Free Full Text]
  19. Shi PY, Kauffman EB, Ren P, Felton A, Tai JH, Dupuis AP, 2nd, et al. High-throughput detection of West Nile virus RNA. J Clin Microbiol 2001;39:1264-1271.[Abstract/Free Full Text]
  20. Yapar M, Aydogan H, Pahsa A, Besirbellioglu BA, Bodur H, Basustaoglu AC, et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse transcriptase-PCR. Jpn J Infect Dis 2005;58:358-362.[Medline] [Order article via Infotrieve]
  21. Pastorino B, Bessaud M, Grandadam M, Murri S, Tolou HJ, Peyrefitte CN. Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African chikungunya viruses. J Virol Methods 2005;124:65-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  22. Wilson IG. Inhibition and facilitation of nucleic acid amplification. Appl Environ Microbiol 1997;63:3741-3751.[Web of Science][Medline] [Order article via Infotrieve]
  23. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.[Abstract/Free Full Text]
  24. Kleiber J, Walter T, Haberhausen G, Tsang S, Babiel R, Rosenstraus M. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn 2000;2:158-166.[Abstract/Free Full Text]
  25. InVS. Chikungunya in La Réunion/Indian Ocean: round-up on 6 October 2006. http://www.invssante.fr/recherche/index2asp?txtQuery=6+octobre+2006..
  26. Lenglet Y, Barau G, Robillard PY, Randrianaivo H, Michault A, Bouveret A, et al. Chikungunya infection in pregnancy: evidence for intrauterine infection in pregnant women and vertical transmission in the parturient: survey of the Reunion Island outbreak [French]. J Gynécol Obstét Biol Reprod 2006;35:578-583.[Medline] [Order article via Infotrieve]
  27. Parida MM, Santhosh SR, Dash PK, Tripathi NK, Lakshmi V, Mamidi N, et al. Rapid and real-time detection of Chikungunya virus by reverse transcription loop mediated isothermal amplification assay. J Clin Microbiol 2007;45:351-357.[Abstract/Free Full Text]
  28. Michault A, Grivard P, Laurent P, Le Roux K, Staikowsky F, Barau G, et al. Diagnostic moléculaire et sérologique d’une infection à chikungunya. RICAI 2006: 26e Réunion Interdisciplinaire de Chimiothérapie Anti-Infectieuse, Palais des Congrès, Paris, France, 2006:101/25o..
  29. Tang Y, Anne Hapip C, Liu B, Fang CT. Highly sensitive TaqMan RT-PCR assay for detection and quantification of both lineages of West Nile virus RNA. J Clin Virol 2006;36:177-182.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  30. Kleinman S, Busch M, Caglioti S, Stramer SL, Dodd R, Strong DM, et al. Update: West Nile virus screening of blood donations and transfusion-associated transmission: United States, 2003. MMWR Morb Mortal Wkly Rep 2004;53:281-284.[Medline] [Order article via Infotrieve]
  31. Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, et al. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006;12:1493-1499.[Web of Science][Medline] [Order article via Infotrieve]
  32. Mishra B, Ratho RK. Chikungunya re-emergence: possible mechanisms. Lancet 2006;368:918.[Web of Science][Medline] [Order article via Infotrieve]
  33. Warner E, Garcia-Diaz J, Balsamo G, Shranatan S, Bergmann A, Blauwet L, et al. Chikungunya fever diagnosed among international travelers: United States, 2005–2006. MMWR Morb Mortal Wkly Rep 2006;55:1040-1042.[Medline] [Order article via Infotrieve]
  34. Krastinova E, Quatresous I, Tarantola A. Imported cases of chikungunya in metropolitan France: update to June 2006. Euro Surveill 2006;11:E060824.1.
  35. Knudsen AB, Romi R, Majori G. Occurrence and spread in Italy of Aedes albopictus, with implications for its introduction into other parts of Europe. J Am Mosq Control Assoc 1996;12:177-183.[Web of Science][Medline] [Order article via Infotrieve]
  36. Schaffner F. Updated data on non-indigenous invasive mosquitoes in Europe, with special reference to France. 15th European Society for Vector Ecology meeting, April 10–14, 2006, Serres, Greece..
  37. Aranda C, Eritja R, Roiz D. First record and establishment of the mosquito Aedes albopictus in Spain. Med Vet Entomol 2006;20:150-152.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  38. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med 2005;353:924-932.[Free Full Text]
  39. Kles V, Michault A, Rodhain F, Mevel F, Chastel C. Sero-epidemiological surveys for Flavivirus infections on Reunion Island (1971–1989). [French]Bull Soc Pathol Exot 1994;87:71-76.[Web of Science][Medline] [Order article via Infotrieve]
  40. Pierre V, Thiria J, Rachou E, Sissoko D, Lassalle C, Renault P. Outbreak of dengue 1 in La Réunion in 2004 [French]. Journées de Veille Sanitaire, Institut National de Veille Sanitaire, Cité des sciences et de l’industrie, Centre des congrès de la Villette, November 29–30, 2005, Paris..




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow 086595.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2007.086595v1
53/8/1408    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Laurent, P.
Right arrow Articles by Michault, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laurent, P.
Right arrow Articles by Michault, A.
Related Collections
Right arrow Molecular Diagnostics and Genetics

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS